- 1 **Title:** Effectiveness of vaccination against symptomatic and asymptomatic
- 2 SARS-CoV-2 infection: a systematic review and meta-analysis
- 3 Meggiolaro A.¹, Sane Schepisi M.¹, Nikolaidis G.², Mipatrini D.¹, Siddu A.¹, Rezza G¹.

4 ABSTRACT

- 5 **OBJECTIVE**: To assess the effectiveness of SARS-CoV-2 vaccines in terms of prevention of disease
- 6 and transmission. The evaluation was narrowed to two mRNA vaccines and two modified
- 7 adenovirus vectored vaccines.
- 8 METHODS: A frequentist random effects meta-analysis was carried out after data extraction. Risk
- 9 of bias of the included studies was assessed using New-Castle-Ottawa Scale. The overall risk of
- SARS-CoV-2 infection confirmed by real time Polymerase Chain Reaction (PCR) was estimated in
- partially and fully vaccinated individuals. The effect size was expressed as Relative Risk (RR) and
- 12 RRR (RR reduction) of SARS-CoV-2 infection after vaccination. Potential sources of heterogeneity
- were investigated through between-study heterogeneity analysis and subgroup meta-analysis.
- 14 **RESULTS:** The systematic review identified 27 studies eligible for the quantitative synthesis.
- 15 Partially vaccinated individuals presented a RRR=73% (95%CI=59%-83%) for any positive SARS-
- 16 CoV-2 PCR (RR=0.27) and a RRR=79% (95%Cl=30%-93%) for symptomatic SARS-CoV-2 PCR
- 17 (RR=0.21). Fully vaccinated individuals showed a RRR=94% (95%CI=88%-98%) for any SARS-CoV-2
- 18 positive PCR (RR=0.06) compared to unvaccinated. According to the subgroup meta-analysis, full
- 19 BNT162b2 vaccination protocol achieved a RRR=84%-94% against any SARS-CoV-2 positive PCR
- and a RRR=68%-84% against symptomatic positive PCR. The RR for any SARS-CoV-2 positive PCR
- 21 remained higher within elderly groups aged ≥69 years (RR=0.12-0.15) compared to younger
- individuals (RR=0.05-0.12). The RR against B.1.351 infection approached 0.40 for any positive PCR
- and 0.36 for symptomatic SARS-COV-2 while the RR of any B.1.1.7 infection was 0.14.
- 24 **CONCLUSION:** The current licensed vaccines may be transmission blocking, especially after full
- 25 vaccination protocol. Given the substantial heterogeneity, results should be interpreted with
- 26 caution. Subgroups meta-analyses suggested that the risk of any SARS-CoV-2 infection may be
- 27 higher for non-B.1.1.7 variants and individuals aged ≥69 years. Further data and longer follow-up
- are required to investigate additional sources of heterogeneity and the effectiveness of SARS-CoV-
- 29 2 vaccination within population subgroups.

STRENGTHS

- Real-world data suggest that the current licensed vaccines may be transmission blocking,
 in particular after full vaccination protocol.
- The risk of any SARS-CoV-2 infection either symptomatic or asymptomatic, may be higher for non-B.1.1.7 variants and individuals aged ≥69 years.

LIMITATIONS

30

31

- Given the substantial heterogeneity encountered in this meta-analysis, results should be interpreted with caution
- Fur ther evidence on the impact of SARS-CoV-2 variants are vital in order to monitor mutations associated with vaccine escape

INTRODUCTION

- 32 Since December 2020, infections with SARS-CoV-2 and the respective disease, COVID-19
- 33 (Coronavirus Disease 2019), have spread worldwide. On 11 March 2020, WHO declared the
- 34 COVID-19 outbreak a pandemic. The Coronavirus disease 2019 (COVID-19) has represented a
- 35 serious threat to public health reporting nearly 4,038,342 deaths and 186,821,815 confirmed cases
- 36 globally. As of 5 July 2021, 3,114,766,865 vaccine doses have been administered.[1]
- 37 Coronaviruses (CoVs), including SARS-CoV, MERS-CoV, and SARSCoV-2, are positive-sense, single
- 38 stranded RNA viruses with four structural proteins (S protein, envelope (E) protein, membrane (M)
- 39 protein, and nucleocapsid (N) protein).[2] The spike protein of SARS-CoV-2 binds to ACE2
- 40 receptors on target cells and acts as immunodominant antigen, eliciting both antibody and T-cell
- 41 responses.[3]
- 42 Most COVID-19 candidate vaccines have been developed including mRNA, adenoviral vectored
- vaccines, inactivated virus, and adjuvanted.[4] During the COVID-19 pandemic, the European
- 44 medicines Agency (EMA) has applied a conditional marketing authorisation for the fast-track
- 45 approval of safe and effective COVID-19 vaccines in the EU. Initially, EMA has recommended three
- 46 COVID-19 vaccines to prevent COVID-19: Comirnaty (BNT162b2), Vaxzevria (ChAdOx1/AZD1222),
- 47 Moderna (mRNA-1273). On March 2021, EMA has further expanded the arsenal of COVID-19
- 48 vaccines available to European member states with the COVID-19 vaccine Janssen (Ad26.COV2.S).
- 49 Each licensed vaccine should meet rigorous standards for safety, efficacy and quality, hence,

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

despite the earlier market authorization, a comprehensive monitoring process is generated postapproval.[5] The vaccines currently authorised in the EU have proven high efficacy in Phase III clinical trial such as Moderna's COVID-19 vaccine with 94.5% efficacy and Pfizer's with 95% efficacy - and likewise, they are expected to be highly effective in the real world. The effort to measure vaccine effectiveness is crucial to encouraging the vaccine uptake and to improving vaccine technology. [6, 7] While efficacy estimate, in terms of degree to which a vaccine prevents disease and/or transmission, is measured under ideal circumstances such as Controlled Randomized Trials (RCTs), effectiveness refers to an estimate of the vaccine performance in the real world. Effectiveness is generally measured through observational studies where participants are not randomly assigned to an intervention versus a control group.[8] The COVID-19 vaccination campaign has offered different options and the vaccines' effect is not necessarily equal.[9-12] The controversy on whether the vaccination is sufficient to prevent any SARS-CoV-2 infection or it merely converts infections from symptomatic to asymptomatic has remained unsolved. Asymptomatic infection following vaccination could still spread the virus and nosocomial COVID-19 infections have been seemingly persistent within health care workers (HCWs), despite the vaccination.[13] The main objective of this study was to estimate the effectiveness of conditional market licensed COVID-19 vaccines in terms of prevention of disease and transmission. The vaccine effectiveness (VE) was measured as relative risk (RR) and relative risk reduction (RRR) of any SARS-CoV-2 infection, confirmed by polymerase chain reaction (PCR) test, on partially and fully vaccinated individuals respect to unvaccinated individuals. The meta-analysis estimated the overall RR of asymptomatic and symptomatic SARS-CoV-2 infections after partial and full vaccination protocol. The evaluation was narrowed to two mRNA vaccines (Comirnaty and Moderna), a modified adenovirus vaccine (COVID-19 Vaccine AstraZeneca or Vaxzevria) and a recombinant human adenovirus vector (Ad26.COV2.S or Janssen or J&J). Worldwide mass vaccination requires evidence synthesis on SARS-CoV-2 VE in order to drive health policy strategies. In particular, VE findings may address policy makers' choices over mitigation measures following mass vaccination campaign, vaccine supply and deployment, vaccination protocol implementation.

METHODS

80

81

83

85

86

92

95

96

98

99

100

101

102

103

104

Protocol registration

The systematic review was prospectively registered on PROSPERO (n. CRD42021240143).

Systematic Review

The systematic review started on March 2021 and was concluded on May 15 2021. The main

purpose of this research was to assess the risk of COVID-19 occurrence (any positive RT-PCR test)

among vaccinated subjects. Moreover, we aimed at quantifying the risk of developing a

87 symptomatic COVID-19 after vaccination. The evaluation was narrowed to BNT162b2, mRNA-

88 1273, ChAdOx1/AZD1222 and Ad26.COV2.S vaccines. This research followed the PRISMA 2020

89 statement.[14]

The search strategy was presented in details in Annex 1. We used seven different web engines,

91 including early stage research platforms: Pubmed, Cochrane, clinicaltrial.gov, and COVID-NMA,

medRxiv, SSRN, and Authorea. No restriction on language, setting or publication date was

93 imposed.

The papers were selected initially by titles and abstracts. The full texts suitable for the quantitative

synthesis were collected in an excel database for the data extraction. The exclusion criteria

included lack of suitable data, and study design. We narrowed the quantitative synthesis to non-

97 experimental studies only.

Data extraction

The data extraction was performed by two authors, independently. The results of the respective

phase III RCTs were used as reference for data extraction.[6, 7, 15, 16] The information derived

from each full text was classified into four categories of information: 1) outcome, 2) study

characteristics (design, publication status, year of publication), 3) participants characteristics

(mean age, severity of COVID-19 symptoms, dose of SARS-CoV-2 vaccine, SARS-CoV-2 lineage) and

4) risk of bias. Disagreements were resolved by discussion or, if necessary, consultation with a

third party.

106 Outcome

107 The primary endpoint of this reasearch was to measure the overall relative risk (RR) of any SARS-

108 CoV-2 infection 14 days after the first dose (partially vaccinated), seven days after the second dose

(fully vaccinated) and 14 days after at least one dose uptake.

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130131

132

133

134

135

136

137

138

139

As secondary endpoint, we aimed at measuring the risk of symptomatic infection following SARS-CoV-2 vaccination, and, if possible, quantifying the risk of hospitalization and death after partial and full vaccination protocol. To this purpose, any COVID-19 infection, either symptomatic or asymptomatic, confirmed through PCR was considered as a COVID-19 case. Studies which did not declare to routinely perform a PCR test after vaccination were excluded. Documented SARS-CoV-2 infections (any positive rtPCR) at the baseline were excluded from the effectiveness analysis. The risk of infection between vaccinated and unvaccinated groups was calculated as relative risk (RR). In order to quantify how much SARS-CoV-2 vaccination reduced the risk of infection relative to the control group, we computed the relative risk reduction (RRR), according to the formula 100x(1-2RR). SARS-CoV-2 infection episodes The primary analysis included the RR of any new positive infection episode among vaccinated and unvaccinated groups confirmed through PCR test. No restriction was imposed to PCR cycle threshold. The impact of SARS-CoV-2 vaccination on infection severity was investigated in secondary analysis as RR of symptomatic positive PCR, and possibly, RR of hospitalization and death following partial and full vaccination protocol. Both self-reported symptoms and symptoms ascertained through clinical visit were included. Finally, COVID-19 episodes were classified as compatible with the B.1.1.7 variant and incompatible (i.e. B.135, non-B.1.1.7, unspecified). Experimental group All adults eligible to undergo SARS-CoV-2 mass vaccination were included in the experimental group. BNT162b2 has been the first vaccine authorized for the emergency rollout, hence, more evidence on effectiveness was expected in the scientific literature. For the definition of case in the vaccinated groups we referred to Polack et al. Phase III RCT.[6] The same rules were applied to ChAdOx1/AZD1222 and mRNA-1273. Concerning ChAdOx1/AZD1222, only few studies on VE after the first dose administration were available, as the vaccine was approved later for the emergency rollout.[15] Ad26.COV2.S single dose administration was considered as full vaccination protocol, although the induction time lasts two weeks (Fig. 1). [16, 47]

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161162

163

164

165

166

167

For each vaccine, the 14 days ensuing the first jab were considered as induction time for building COVID-19 immunogenity, therefore, SARS-CoV-2 cases occurred within two weeks from the first dose were not included.[6, 17] In order to assess the effectiveness of full vaccination protocol, the upper follow-up limit was set at seven days after the second dose. (Fig.1) Only SARS-CoV-2 cases occurred at least one week after the second dose were attributed to the lack of vaccine protection.[6] Moreover, cases occurred within these seven days were still attributed to the first dose effectiveness (Fig.1). VE against any positive SARS-COV-2 on at least one dose, was tested after 14 days from the first dose administration. FIGURE 1 Control group In the general population, the mean incubation period for COVID-19 symptoms onset was estimated as 5.8 days.[18] Insofar, vaccination has been prioritized towards older and at-risk individuals and this aspect might bias the comparison with the unvaccinated cohort, which generally was younger and healthier. Overall, cohort studies drew the control group from the same population as the vaccinated group, while in few cases the cohort was the same community observed before-after the vaccination. For reasons mostly related to dearth of detailed information on unvaccinated individuals, the beginning of the follow-up for the control group was established at TO (Fig.1). Risk of bias In order to assess the risk of bias, we employed the Newcastle-Ottawa Scale (NOS) in cohort and case-control studies, and the NOS adapted for cross-sectional studies. For systematic review and meta-analysis, we used AMSTAR 2 checklist.[49] Statistical analysis We performed a frequentist meta-analysis using the inverse variance (IV) method. [19] In addition, the Mantel-Haenszel (MH) method was applied because we expected to encounter sparse data, especially in estimating the RR of symptomatic cases after vaccination. The analysis was executed on R (version 4.0.5).

169

170

171

172

173

174

175

176

177

178

179

180

181182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

In the early phases of the mass vaccination campaign we expected the selected studies to be statistically heterogeneous. The main assumption underpinning the fixed effect model (FE) is that the true effect size is the same in all studies. This assumption was implausible in this systematic review, as the SARS-CoV-2 vaccination campaign has targeted priority population subgroups in the early stages. Therefore, the random effect (RE) meta-analysis was considered more appropriate to estimate the overall effect size. However, both FE and RE outputs were reported. In order to test for the overall heterogeneity both the Cochran's Q (chi-squared statistic) and I-squared values (I^2) were calculated. The Der Simonian and Laird method estimated the between studies variance τ2.[20] As the between-study heterogeneity can be caused by studies with extreme effect size, low quality or small sample size, the outliers test was implemented in order to detect which studies did not fit in the meta-analysis. Moreover, we explored the robustness of our meta-analyses results using influence analyses.[21] The Baujat Plot displayed which studies overly contributed to the heterogeneity, [22] while the leave-one-out analysis recomputed the pooled effect size and the 12 with one study omitted at each step (Annex 3). The Graphic Display of Heterogeneity (GOSH) with Knapp-Hartung adjustment fits the meta-analysis model over all possible subsets of the included studies.[23] Three clustering algorithms detect potential patterns in the data distribution. GOSH analysis allows the identificantion of the studies that contribute to the overall heterogeneity and, possibly, to derive subgroup analysis therefrom (Annex 3).[20] The subgroups meta-analysis was performed to identify further heterogeneity sources. [24] As we expected a limited number of studies in some subgroups (n<10), we opted for a FE model in subgroup meta-analysis. The subgroup levels were considered fixed and exhaustive. Nevertheless, RE and mixed model were added to the output, in order to catch discrepancies that might yield to inconclusive results (reported in Annex 4.1). In mixed model (or fixed plural model), subgroups are assumed to share a common estimate of the between-study heterogeneity. However, the general approach was to evaluate a separate τ^2 across subgroups when the number of studies was greater than five, because the estimate of τ^2 may be imprecise when the number of studies in a subgroup is smaller (i.e. n≤5).[20, 25] The subgroups meta-analysis enclosed vaccine type, quality, age of vaccinated population, and SARS-CoV-2 lineage detected through PCR tests. Although five or more studies were needed to

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217218

219

220

221

222

223

224

225

226

227

consistently achieve power from random effects meta-analysis, given a need for a conclusion, two studies were considered sufficient for the statistical inference.[26, 27] In order to test whether publication biases have influenced the study conclusions we performed a funnel plot (Annex 4.2).[28] Results The web search provided 7,760 unduplicated records. Overall, 31 studies were selected for data extraction and qualitative data synthesis. (Fig. 5, Annex 2). There were 24 cohort studies, two case-control, one cross sectional, one matched observational, and three test negative casecontrol. Ten studies were performed in UK, eight in US, and five in Israel. RR of SARS-CoV-2 infection among Health care workers (HCWs) was examined by 13 studies; four studies analysed long term care facilities (LCTF) residents and nine the general population. (Tab.3, Annex 2) Qualitative synthesis Four studies met the inclusion criteria for the systematic review but were not included in the quantitative analyses. [50, 53, 54, 55] A study from Israel assessed the BNT162b2 effectiveness through national surveillance system. The study reported significant VE for asymptomatic SARS-CoV-2 infection (90.4%), symptomatic COVID-19 disease (96.3%), hospitalization (96.0%), severe and critical hospitalization (96.2%), and death (93.3%).[50] Drury et al. conducted a study through the COVID Symptom Study app in UK. The results showed a progressive risk reduction for SARS-CoV-2 infections among vaccinated over time. Both BNT162b2 (risk reduction increased from 58% to 72%) and ChAdOx1/AZD1222 (risk of infection increased from 39% to 60%) single dose effectiveness was tested against unvaccinated subjects.[53] In a prospective cohort study conducted among frontline HCWs in US, Thompson et al. reported 90% VE for full immunization and 80% for partial immunization.[54] In a prospective cohort-study conducted on population registries in Scotland, Vasilieu et al. evaluated the effectiveness of BNT162b2 and ChAdOx1/AZD1222 single dose administration against COVID-19 hospitalization. VE was 85% for BNT162b and 94% for ChAdOx1 /AZD1222.[55] Meta-analysis In the following meta-analysis a RE model with inverse variance (IV) method was used throughout. The evidence synthesis was based on RR as measure of effect. Additionally, the FE estimates as

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254255

256

257

well as the Mantel-Haenszel outputs were reported in Table 1. The between-study variance τ^2 was computed for each RE meta-analysis. Overall, 27 out of 31 studies were included in the meta-analysis. Despite some small sample sizes and few infection cases expected among vaccinated individuals, no study presented zero cells during the data extraction. ChAdOx1/AZD1222 effectiveness was investigated in 4 out of 27 studies, [31, 32, 51, 52] while only one study estimated Ad26.COV2.S effectiveness.[47] The Newcastle-Ottawa Quality Assessment Scale showed a satisfactory quality, with a median NOS score of six, a minimum of five and a maximum of eight.[29] RR of SARS-CoV-2 infection following vaccination The meta-analysis on first dose VE against any positive PCR pooled 17 studies and 22 entries. Jones' analysis spanned over a follow-up of two weeks (A) and, additionally, an extended period of six weeks (B).[30] Bernal et al. evaluated the effectiveness of one and two doses of BNT162b2 vaccine on adults aged ≥ 80 years (A80 and B80) and ≥70 years (B70 and C70) in England. Additionally, the effectiveness of ChAdOx1/AZD1222 single dose (A70) and BNT162b2 one dose at least (C70) were tested on adults aged ≥ 70 years (A70).[31] Shotri et al. estimated the protective effects of BNT162b2 (A) and ChAdOx1/AZD1222 (B) first dose against any SARS-CoV-2 infection.[32] One study from Denmark investigated BNT162b2 VE in two cohorts, namely longterm care facility residents (R) and HCWs (H).[33] Abu Raddad et al. measured the effectiveness of BNT162b2 against B.1.1.7 (A), B.1.351 (B), which became predominant within Qatar in the earliest 2021, and any different (C) SARS-CoV-2 variants.[34] According to the RE meta-analysis results (IV), partially vaccinated showed a RRR=73% of any SARS-CoV-2 positive PCR compared to unvaccinated (RR=0.27). The FE model yielded lower effectiveness estimates after partial vaccination (RR=0.41; RRR=59%). Although both FE and RE (IV) showed a statistically significant result (p< 0.0001), the heterogeneity was considerable (τ^2 =1.08; H = 18.43 [17.52; 19.38]; I² = 99.7%); therefore the true size of the effect remained uncertain (Table 1, Fig.2a). In the evaluation of the RR for any positive SARS-CoV-2 PCR following full vaccination protocol, only data on mRNA vaccines (BNT162b2 and mRNA-1273) were available. Sixteen studies and 17 entries were included in this meta-analysis. One study evaluated Ad26.COV2.S effectiveness, whilst "Pritchard" indistinctly assessed the effectiveness of ChAdOx1/AZD1222 and BNT162b2 after full vaccination protocol.[35] In "Abu Raddad" study, data on PCR test were available after

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

two weeks from the BNT162b2 second dose administration.[34] Four studies did not distinguish between BNT162b2 and mRNA-1273 vaccines.[36-39] Basing on the RE meta-analysis results (IV), the RRR for any positive SARS-CoV-2 PCR following full vaccination protocol was 94% (95%CI=88%-98%) with RR=0.06 compared to unvaccinated individuals (Table 1, Fig.2b). FE yielded a RRR=88%. Although both FE and RE showed a statistically significant protective effect of full COVID-19 vaccination (p< 0.0001), we should carefully draw conclusion over the true size effect because the heterogeneity was considerable $(\tau^2=2.6; H=10.07)$ $[9.22; 11.00]; I^2=99.0\%$). The test for heterogeneity was significant at 1% (Q= 1621.96, p=0). (Table 1, Fig.2b). A longer follow-up period represented the main advantage of VE estimation after at least one dose uptake. The mean length of follow-up was indeed 54 days after the first dose administration. The meta-analysis on RR of testing positive for any SARS-CoV-2 PCR included 18 entries and 14 studies. Menni et al. analysed the SARS-CoV-2 infection events on individuals who received one or two doses of BNT162b2 (A) and ChAdOx1/AZD1222 (B).[52] The results of RE meta-analysis (IV) produced a significant RRR=84% for vaccinated individuals compared to unvaccinated, with RR=0.26. The test for heterogeneity was significant at 1% (Q=1030.89, p<0.0001). (Table 1, Fig.2c) In order to assess the effectiveness of SARS-CoV-2 vaccination against symptomatic COVID-19 infection, we performed two meta-analyses, in partially and fully vaccinated individuals (Table1). The meta-analysis on full vaccination protocol included only studies estimating VE among individuals aged <69 years. The meta-analyses on VE against symptomatic SARS-CoV-2 infection pooled 9 studies and 17 entries in total. In particular, nine and eight entries pertained to partial and full vaccination protocols respectively. The IV method displayed significant results for both FE and RE (p< 0.05). According to the RE results (IV), partial vaccination achieved a RRR=78% (95%CI= 31%-93%) for symptomatic SARS-CoV-2 infection compared to unvaccinated, while fully vaccinated subjects exhibited a RRR= 94% (95%CI=84%-98%) (Fig.3a, b). FE estimates of RRR were lower for both partially and fully vaccinated individuals (RRR=51% and RRR=76%, respectively). Both FE and RE were statistically significant (p<0.05). Concerning hospitalization risk, a RE meta-analysis over 2 studies, [31, 40] produced a RR=0.38 (95%CI=0.2719; 0.5242) after a full BNT162b2 vaccination protocol. (Q= 2.04, p= 0.1529; I2 = 51.1% [0.0%; 87.6%]). Basing on Bernal et al. data, at least one dose of BNT162b2 vaccine ensured a RRR of death equal to 83%, compared to unvaccinated individuals.[31]

Considering the substantial heterogeneity and the significance of the heterogeneity test, we could not be overly confident that the RR estimate would be robust in every context; therefore, we performed a sensitivity analysis to address the between-study heterogeneity (Annex 3).

Table 1) Meta-analyses: relative risk of SARS-CoV-2 of positive PCR test after vaccination. Fixed (FE) and Random Effect (RE), inverse variance method (IV) and Mantel-Haenszel (MH) method. RR of any positive PCR and symptomatic positive PCR after SARS-CoV-2 vaccination. Any SARS-CoV-2 vaccination protocol.

		SARS-CoV-2		SARS-CoV-2		SARS-CoV-2		SARS-CoV-2		SARS-CoV-2		Fixed effect mod	lel	Random effect mo	del		
Method	PCR test	vaccination protocol	N	RR [95%-CI]	p-value	RR [95%-CI]	p-value	τ²	12								
		Partially vaccinated	22	0.4115 [0.4025; 0.4207]	0	0.2657 [0.1710; 0.4127]	< 0.0001	1.0747 [0.6223; 3.0350]	99.70%								
	any positive PCR	Fully vaccinated	17	0.1204 [0.1120; 0.1295]	0	0.0586 [0.0266; 0.1292]	< 0.0001	1.6228 [1.0654; 2.4896]	99.00%								
Inverse Variance		At least one dose	18	0.3813 [0.3752; 0.3875]	0	0.1617 [0.1130; 0.2313]	< 0.0001	0.5862 [0.4444; 2.6714]	99.70%								
(IV)	symptomatic	Partially vaccinated	9	0.4885 [0.4658; 0.5122]	< 0.0001	0.2181 [0.0685; 0.6944]	0.01	3.0607 [0.7297; 10.0860]	99.50%								
	positive PCR test	Fully vaccinated	8	0.2439 [0.2231; 0.2666]	< 0.0001	0.0629 [0.0245; 0.1613]	< 0.0001	1.7560 [1.1035; 14.6961]	98.80%								
		Partially vaccinated	22	0.2490 [0.2436; 0.2546]		0.2656 [0.1617; 0.4363]		1.374									
N/14-1	any positive PCR	Fully vaccinated	17	0.0447 [0.0419; 0.0477]		0.0586 [0.0228; 0.1505]		3.7986									
Mantel- Haenszel	PCK	At least one dose	18	0.3369 [0.3315; 0.3424]		0.1616 [0.1122; 0.2328]		0.6083									
(MH)	symptomatic	Partially vaccinated	9	0.2758 [0.2644; 0.2878]	0	0.2182 [0.0567; 0.8388]	0.0267	4.1669	99.60%								
()	positive PCR test	Fully vaccinated	8	0.0811 [0.0752; 0.0874]	0	0.0626 [0.0167; 0.2344]	< 0.0001	3.5394	99.40%								

298 FIGURE 2 a,b,c

300 FIGURE 3 a,b

L' Abbé plot

The L' Abbé plots in Fig.4 confirmed that, overall, infection events were in favour of the control group (unvaccinated). Regarding the meta-analysis on any positive SARS-CoV-2 PCR case after partial vaccination, no study laid above the 45° except "Dagan" and "Angel", which overlapped the line of no-effect (Fig.4a), while "Dagan" contributed the most to the overall effect size.[11, 46] Three studies clearly deviated from the effect-size line in Fig.4a,[34, 38, 41] and this might explain the highest heterogeneity encountered in these data. Four studies were very small and less precise.[38, 41-43] In fully vaccinated meta-analysis (Fig4b), "Pawloski" crossed the no-effect line, while "Abu-Raddad B" and "Hall" evidently deviated from the dashed line of the pooled effect. In

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

Fig.4c "Hall" and "Lopez Bernal≥80" diverged from the overall RE estimate (light dashed line), while "Monge" appeared as the largest sample sized. [31, 44] Concerning symptomatic SARS-CoV-2 infections, the L'Abbè plots in Fig.4d) and 4e) confirmed that the infection rates were greater in unvaccinated groups than partially or fully vaccinated groups. Overall, "Dagan", "Jones", and "Abu-Raddad" were the largest sized studies (Fig.4d and 4e).[11, 13, 45] In Fig.4d, "Dagan" partially overlapped the 45° line. No study frankly diverged from the light dashed line (RE overall RR) except "Hyams".[11, 45] FIGURE 4 a,b,c,d,e Subgroup meta-analysis The GOSH analysis did not indicate any clear cluster that contributed to the pooled imbalance (Annex 3). In the subgroup meta-analysis, we grouped the studies by type of vaccine, mean age of the sample (≥69 and < 69 years), SARS-CoV-2 lineage, and bias assessment performed through Newcastle-Ottawa Scale (NOS). We classified NOS quality score into satisfactory (NOS ≤6) and good (NOS >6).[29] The meta-analysis was performed over two studies at least.[27] The results of FE model were presented in Tab.2 while mixed and RE subgroup meta-analyses were attached in Tab.10 and 11 (Appendix 4.1). The FE subgroup meta-analysis broadly explained the betweenstudy heterogeneity because all subgroups produced a significant Q test (p< 0.0001). However, considered the residual heterogeneity and the small number of studies in several subgroups, results must be interpreted with caution. The first subgroup analysis compared different vaccine technologies. Basing on FE subgroup estimates, the RRR after BNT162b2 first dose ranged from 46% to 49% for any positive SARS-COV-2 PCR and from 35% to 32% for symptomatic events. The discrepancy might be explained by the low number of studies included in the subgroup evaluating VE against symptomatic SARS-COV-2 infection (n=6) with respect to the group evaluating the effectiveness of BNT162b2 vaccine against any positive PCR (n=16) (Table 2). Only one study assessed the effectiveness of ChAdOx1/AZD1222 against symptomatic PCR (RR=0.34), however, the effect size was probably overestimated. Corchado et al. analysis suggested a RRR=77% for Ad26.COV2.S,[47] while "Pritchard" did not distinguish between BNT162b2 and ChAdOx1/AZD1222 in VE analysis.[35] In FE the RR estimates were greater within high quality studies (NOS>6), either symptomatic or not (RR=0.12 and RR=0.07 respectively) compared to satisfactory studies (NOS≤6, RR=0.67 and RR=0.48, respectively). Partial

vaccination effectiveness appeared lower within studies which examined older population (≥69

years) compared to younger, either on symptomatic PCR (RR= 0.40 and RR= 0.49, respectively) or any positive PCR (RR=0.29 and RR= 0.48, respectively).

Regarding the FE subgroup meta-analysis in fully vaccinated (Table 2), BNT162b2 produced a RRR=83% against any positive PCR and a RRR=68% against symptomatic SARS-CoV-2 infections. The RE and the mixed model produced a RRR=94% against any positive PCR and RRR=84% against symptomatic COVID-19. Further, the FE subgroup meta-analysis relative to the bias assessment (NOS) showed a greater RR for low quality studies with respect to high quality studies (RR=0.01 in symptomatic PCR and RR=0.33 in any positive PCR meta-analyses, respectively). Full vaccination effectiveness against any positive PCR appeared slightly lower within studies which examined older population (≥69 years) compared to younger (RR=0.15 and RR= 0.12, respectively).

Concerning partial vaccination effectiveness against SARS-CoV-2 variants, the RRR of any positive PCR for B.1.1.7 resulted nearly 60% in FE and 81% in mixed model. The RRR increased to 85% in FE and 92% in mixed model after full vaccination. Although only "Abu Raddad" assessed the effectiveness of BNT162b2 against B.1.351 lineage,[34] the RRR was lower for the B.1.351 variant in both partially (RRR=9%) and fully vaccinated subjects (RRR=60%). Regarding symptomatic PCR, the RRR within fully vaccinated individuals remained higher for B.1.1.7 (RRR=86%) with respect to B.1.351 (RRR=64%) (Table 5a, b, e).

Table 2) Subgroup meta-analysis, any SARS-CoV-2 protocol. Fixed effect model.

Subgroups			Results for sul	Between-groups heterogeneity				
			RR [95%-Cl]	12	tau2	Q	df(Q)	p-value
a) Partiall	y vaccinated, any positive PCR - fixe	d e ffe	ct	•	•			
Vaccine	BNT162b2	16	0.5250[0.5123; 0.5381]	99.60%	0.7549	3108.43	3	0
	ChAdOx1/AZD1222	2	0.2277[0.2122; 0.2443]	98.90%	0.3565			
	BNT162b2/mRNA-1273	3	0.2778[0.2474; 0.3120]	98.80%	1.0692			
	BNT162b2/ChAdOx1/AZD1222	1	0.0357[0.0323;0.0393]					
Quality	NOS ≤6	15	0.4816[0.4704; 0.4931]	99.60%	0.6113	1502.28	1	0
	NOS >6	7	0.1219[0.1142; 0.1302]	99.70%	3.3748			
Age	< 69 years	15	0.4828[0.4702; 0.4958]	99.80%	1.5669	463.24		< 0.0001
	≥ 69 years	7	0.2845[0.2733; 0.2962]	98.60%	0.2424			
Lineage	B. 1. 1. 7	8	0.3903[0.3777; 0.4033]	99.70%	0.9447	3031.61	3	0
	B. 1. 1. 7/n on B. 1. 1. 7	5	0.1492[0.1418; 0.1569]	99.70%	1.4303			
	not specified	8	0.3254[0.2971; 0.3565]	97.10%	0.6506			
	B. 1.351	1	0.9080[0.8717;0.9458]					
b) Fully va	accinated, any positive PCR - fixed	effect		•	•			
Vaccine	BNT162b2	11	0.1680 [0.1537; 0.1836]	98.40%	1.7775	702.84	3	< 0.0001
	BNT162b2/mRNA-1273	4	0.1624 [0.1394; 0.1893]	98.90%	3.7392			
	BNT162b2/ChAdOx1/AZD1222	1	0.0062 [0.0049; 0.0078]					
	Ad26.COV2.S	1	0.2338 [0.0745; 0.7337]					
Quality	NOS ≤6	11	0.1947 [0.1797; 0.2108]	98.50%	1.3935	827.35	1	< 0.0001
	NOS >6	6	0.0112 [0.0094; 0.0134]	95.90%	1.6474			
Age	< 69 years	13	0.1171 [0.1084; 0.1266]	99.30%	3.0726	4.21	1	0.0403
	≥ 69 years	4	0.1487 [0.1200; 0.1843]	65.00%	0.2931			
Lineage	B. 1. 1. 7	4	0.1448 [0.1231; 0.1703]	95.90%	0.817	1000.54	3	< 0.0001
	B. 1. 1. 7/n on B. 1. 1. 7	5	0.0190 [0.0165; 0.0219]	98.60%	1.9969			

	not specified	7	0.1692 [0.1452; 0.1971]	97.70%	3.4732			
	B. 1.351	1	0.4027 [0.3533; 0.4592]					
c) At least	t one dose, any positive PCR - fixed	effect						•
Vaccine	BNT162b2	12	0.2575 [0.2511; 0.2640]	99.60%	0.6218	2752.22	2	0
	BNT162b2/mRNA-1273	4	0.5641 [0.5517; 0.5767]	98.50%	0.4039			
	ChAdOx1/AZD1222	2	0.1462 [0.1354; 0.1578]	83.10%	0.2114			
Quality	NOS ≤6	16	0.2550 [0.2491; 0.2610]	99.40%	0.432	2182.95	1	0
	NOS >6	2	0.5525 [0.5402; 0.5650]	99.90%	8.9219			
Age	< 69 years	12	0.2196 [0.2133; 0.2260]	99.30%	0.5076	2070.75	1	0
	≥ 69 y ears	6	0.4927 [0.4832; 0.5025]	99.80%	0.5585			
Lineage	B. 1. 1. 7	4	0.3357 [0.3223; 0.3497]	99.80%	0.8863	1015.58	2	< 0.0001
	B. 1. 1. 7/n on B. 1. 1. 7	5	0.1463 [0.1372; 0.1560]	95.00%	0.3366			
	not specified	9	0.4231 [0.4154; 0.4310]	99.80%	0.5975			
d) Partiall	ly vaccinated, symptomatic positive	PCR-	fixed effect	•	•			•
Vaccine	BNT162b2	6	0.6572 [0.6245; 0.6915]	99.60%	1.1044	1414.28	3	< 0.0001
	ChAdOx1/AZD1222	1	0.3441 [0.1763; 0.6715]					
	BNT162b2/mRNA-1273	1	0.5552 [0.4336; 0.7111]					
	BNT162b2/ChAdOx1/AZD1222	1	0.0270 [0.0231; 0.0317]					
Quality	NOS ≤6	6	0.6688 [0.6354; 0.7039]	99.60%	0.7447	1057.05	1	< 0.0001
	NOS >6	3	0.0676 [0.0595; 0.0769]	99.50%	3.5694			
Age	< 69 years	7	0.4902 [0.4673; 0.5143]	99.60%	3.384	1.25	1	0.2636
	≥ 69 years	2	0.3962 [0.2736; 0.5737]	0.00%				
Lineage	B. 1. 1. 7	3	0.2410 [0.1801; 0.3224]	89.10%	0.5695	26.49	3	< 0.0001
	B. 1. 1. 7/n on B. 1. 1. 7	2	0 5032 [0 4789; 0 5287]	99.90%	5.242			
	not specified	4	0.4116 [0.3326; 0.5094]	94.10%	1.3278			
e) Fully va	accinated, symptomatic positive PC	R fixe	ed model	•				•
Vaccine	BNT162b2	6	0.3181 [0.2901; 0.3489]	94.90%	0.3245	488.27	2	< 0.0001
	BNT162b2/ChAdOx1/AZD1222	1	0.0021 [0.0012; 0.0036]					
	BNT162b2/mRNA-1273	1	0.0131 [0.0086; 0.0200]					
Quality	NOS ≤6	5	0.3301 [0.3008; 0.3622]	93.00%	0.1911	492.15	1	< 0.0001
•	NOS >6	3	0.0085 [0.0063; 0.0116]	94.60%	1.4624			
Lineage	B. 1. 1. 7	2	0.1347 [0.1034; 0.1753]	94.80%	1.565	222.39	3	< 0.0001
-	B. 1. 1. 7/n on B. 1. 1. 7	3	0.2744 [0.2408; 0.3127]	99.40%	6.8062			
	not specified	2	0.0166 [0.0111; 0.0248]	91.80%	2.5779			
	B.1.351	1	0.3598 [0.3111; 0.4162]	31.0070	5,,5			
	D. T. 3.3 T	1	0.5556 [0.5111, 0.4162]					

Publication bias

The funnel plots were displayed in Fig.26 (Annex 4.2). The contour-enhanced funnel plots did not exhibit publication bias. The majority of the studies fell into p<0.01 except "Tenforde" (Fig.26 a, d). The Egger test indicated the presence of funnel plot asymmetry in meta-analysis for symptomatic SARS-CoV-2 RR after full vaccination protocol (intercept=-11.271, p=0.026), although it may lack the statistical power to detect bias, because the number of studies was small (n<10).

DISCUSSION

Despite the considerable between-study heterogeneity, our findings provided evidence that any COVID-19 vaccine is highly effective outside the controlled conditions of the clinical trials. Overall, SARS-CoV-2 vaccination is effective in reducing the number of new COVID-19 events, either asymptomatic or symptomatic, with the greatest benefit achieved after completing the full vaccination protocol. Fewer real-world data were available for ChAdOx1/AZD1222 due to its later regulatory approval. Yet, vaccination with ChAdOx1/AZD1222 resulted in the rare onset of

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

immune thrombotic thrombocytopenia; therefore, it underwent an additional careful monitoring process by European Union (EU) regulatory authorities. [48] According to our findings, partially vaccinated individuals were only one-fourth as likely (RR=0.26) to develop any SARS-CoV-2 infection, as were unvaccinated individuals; whilst the overall risk of symptomatic infection was slightly lower (RR=0.22). The full vaccination schedule was effective at 94% against asymptomatic and symptomatic positive PCR tests. Concerning hospitalization risk, a meta-analysis over two studies, [31, 40] yielded a RRR=62% ensuing a full BNT162b2 vaccination protocol. Concerning mortality risk, our findings corroborated Bernal et al. study,[31] conducted over 7.5 million adults aged 70 years and older in UK. At least one dose of BNT162b2 was approximately 83%, effective at preventing death compared to unvaccinated individuals, while there was insufficient follow-up to assess ChAdOx1/AZD1222 impact on mortality because of the later rollout. The subgroup analysis did not find any significant difference in effectiveness between the mRNA and the modified adenovirus vaccines, in part because the evidence, especially for ChAdOx1/AZD1222, was still very scarce. Up to May 15, only two studies evaluated ChAdOx1/AZD1222,[31, 32, 51, 52] and only one Ad26.COV2.S effectiveness.[47] As expected, COVID-19 VE appeared higher in adults aged <69 years. The evaluation of VE against the SARS-CoV-2 variants remained a key point that lacked of robustness in results. In fact, only one study investigated the effectiveness of BNT162b2 against two variants of concern.[34] The RR of infection following a full vaccination protocol appeared larger for B.1.351 (South Africa) variant compared to B.1.1.7 (UK). Although the evidence suggested a lower VE against SARS-COV-2 variants of concern, our findings were not sufficient to assert that COVID-19 full vaccination protocol is 60% effective against B.1.351 and 94% effective against B.1.1.7. Our research aimed at addressing questions not answered by clinical trials, by including nonrandomized studies undertaken after vaccine licensure. Moreover, we attempted to assess VE within different subgroups not included in the preauthorization vaccine clinical trials. Although imprecise, real world data confirmed the experimental evidence. Nevertheless, the lower level of protection assured against emerging variants of concern encouraged to pursue an accurate and robust VE validation. This systematic review acknowledged several limitations. Undeniably, the expected heterogeneity stemmed from the observational design of the included studies. Unless a randomized process, it is

unlikely to be reduced in any circumstances. Moreover, several studies lacked of data on population characteristics. For instance, the meta-analysis predominantly included Caucasian populations whereas vaccines may have different effectiveness across individuals from different ethnicities. Moreover, five studies did not declare to test systematically the vaccinated cohort during the follow-up. The absence of active laboratory surveillance within vaccinated individuals might have resulted in an underestimation of asymptomatic cases. However, we did not consider a different rate of testing as a bias of concern in terms of RR estimate, because both vaccinated and unvaccinated individuals underwent the same case investigation and contact tracing protocol. Moreover, when systematic testing was not performed, asymptomatic testing was available to different extent: workplace exposures (HCWs), out-of-state travellers or per-request.[37] In general, SARS-CoV-2 PCR testing was highly accessible and free of charge.[11, 50] However, asymptomatic cases which progressed into symptomatic disease could act as source of bias in both vaccinated and unvaccinated groups.[37, 43] Finally, public health mitigation measures might contribute to the underestimation of SARS-CoV-2 vaccine effectiveness. Unfortunately, the extent to which primary prevention restrictions affected VE was beyond the scope of this study. By way of conclusion, we can state that significant reduction in RR of asymptomatic infection within partially vaccinated was not corroborated by sufficient statistical robustness for the generalizability of results. However, full vaccination effectiveness over symptomatic and asymptomatic SARS-CoV-2 infections risk, confirmed the RCTs results, except larger CI. To the best of our knowledge, this is the first evidence-based data synthesis on SARS-CoV-2 VE. Our findings support the maximization of the full vaccination coverage and encourage a better calibration of the statistical inference as the mass vaccination wears on. Long-term vaccine effectiveness remains unexplained and needs further investigation. Better evidence over the impact of SARS-CoV-2 variants are vital in order to monitor mutations associated with vaccine escape.

AUTHOR AFFILIATIONS:

405

406

407

408

409

410

411

412

413

414

415

416

417

418 419

420

421

422

423

424

425

426

427

428

429

430

431

432

433 1 Italia Ministero della Salute Direzione generale della prevenzione sanitaria 434 Roma, Lazio, IT - Italian Ministry of Health, HQ, General Directorate of Prevention, Rome, Italy

- 435 2 IQVIA, London, 210 Pentonville Road N19JY, United Kingdom
- 436 **Corresponding author**:
- 437 Meggiolaro Angela, MD, MSc, PhD
- 438 Italian Ministry of Health, HQ
- 439 General Directorate of Prevention
- 440 Viale G.Ribotta, Rome (IT)
- 441 a.meggiolaro@sanita.it

- 443 **FUNDING:** This work was supported by the Italian Ministry of Health.
- 444 **COMPETING INTERESTS:** none.
- 445 **ETHICS APPROVAL STATEMENT**: No ethics committee approval was required.
- 446 **CONTRIBUTORSHIP STATEMENT:** Each named author has substantially contributed to conducting
- the underlying research and writing the paper.
- 448 DATA SHARING STATEMENT: this manuscript does not contain personal and/or medical
- 449 information about identifiable individuals. The study protocol is available at PROSPERO web
- 450 registry (n. CRD42021240143). The statistical analysis plan is available upon request from the
- 451 Authors.


453

452 **PATIENT AND PUBLIC INVOLEMENT:** patients were involved by primary studies.


REFERENCES

- 454 1. (https://coviD19.who.int/ accessed 13.07.2021)
- 2. Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis.
- 456 Journal of medical virology. 2020 Apr;92(4):418-23.
- 457 3. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, Dejnirattisai W, Rostron T, Supasa P, Liu C, Lopez-
- 458 Camacho C. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK
- 459 convalescent individuals following COVID-19. Nature immunology. 2020 Nov;21(11):1336-45.
- 460 4. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK,
- 461 Angus B, Babbage G, Belij-Rammerstorfer S. Safety and immunogenicity of ChAdOx1 nCoV-19
- 462 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind,
- 463 randomised, controlled, phase 2/3 trial. The Lancet. 2020 Dec 19;396(10267):1979-93.
- 464 5. (https://www.ema.europa.eu/en/medicines accessed 13.07.2021)

- 465 6. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Marc GP, Moreira ED,
- 466 Zerbini C, Bailey R. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. New England
- Journal of Medicine. 2020 Dec 10.
- 468 7. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N,
- 469 Creech CB, McGettigan J. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England
- 470 Journal of Medicine. 2021 Feb 4;384(5):403-16.
- 471 8. (https://www.gavi.org/vaccineswork/what-difference-between-efficacy-and-effectiveness;
- 472 accessed 13.07.2021)
- 473 9. Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel using aggregated counts.
- 474 MedRxiv. 2021 Jan 1.
- 475 10. Chodick G, Tene L, Patalone T, Gazit S, Ben-Tov A, Cohen D, Muhsen K. The Effectiveness of the First
- 476 Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World Evidence. Available at
- 477 SSRN 3769977. 2021 Jan 20.
- 478 11. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer
- 479 RD. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. New England
- 480 Journal of Medicine. 2021 Apr 15;384(15):1412-23.
- 481 12. Rossman, H. et al. Patterns of COVID-19 pandemic dynamics following deployment of a broad
- 482 national immunization program. (2021) doi: 10.1101/2021.02.08.21251325.
- 483 13. Jones NK, Rivett L, Seaman S, Samworth RJ, Warne B, Workman C, Ferris M, Wright J, Quinnell N,
- 484 Shaw A, Goodfellow IG. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2
- 485 infection. Elife. 2021 Apr 8;10:e68808.
- 486 14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ,
- 487 Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of
- 488 studies that evaluate health care interventions; explanation and elaboration. Journal of clinical
- 489 epidemiology. 2009 Oct 1;62(10):e1-34.
- 490 15. Voysey M, Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL,
- 491 Bhorat QE, Bibi S. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-
- 492 CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
- 493 The Lancet. 2021 Jan 9;397(10269):99-111.
- 494 16. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C,
- 495 Fennema H, Spiessens B, Offergeld K. Safety and efficacy of single-dose Ad26. COV2. S vaccine
- 496 against COVID-19. New England Journal of Medicine. 2021 Jun 10;384(23):2187-201.
- 497 17. Rothman KJ, Greenland S, Lash TL. Modern epidemiology. Philadelphia: Wolters Kluwer
- 498 Health/Lippincott Williams & Wilkins; 2008 Sep 20.



order addits in England, Medixiv, 2021 Jan 1.



- Tut G, Bernal JL. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against
- 535 SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective
- 536 cohort study. The Lancet Infectious Diseases. 2021 Jun 23.
- 537 33. Moustsen-Helms IR, Emborg HD, Nielsen J, Nielsen KF, Krause TG, Molbak K, Moeller KL, Berthelsen
- 538 AS, Valentiner-Branth P. Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA
- 539 COVID-19 Vaccine in long-term care facility residents and healthcare workers-a Danish cohort
- 540 study. MedRxiv. 2021 Jan 1.
- 541 34. Abu-Raddad LJ, Chemaitelly H, Butt AA. Effectiveness of the BNT162b2 COVID-19 Vaccine against
- the B. 1.1. 7 and B. 1.351 Variants. New England Journal of Medicine. 2021 May 5.
- 543 35. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O, Vihta KD, Jones J, House T,
- VanSteenHouse H, Bell J, Bell JI. Impact of vaccination on new SARS-CoV-2 infections in the UK.
- 545 medRxiv. 2021 Jan 1.
- 546 36. Mody A. Review 1:" FDA-authorized COVID-19 vaccines are effective per real-world evidence
- 547 synthesized across a multi-state health system". Rapid Reviews COVID-19. 2021 Apr 26.
- 548 37. Bouton TC, Lodi S, Turcinovic J, Weber SE, Quinn E, Korn C, Steiner J, Schechter-Perkins EM, Duffy E,
- Ragan EJ, Taylor BP. COVID-19 vaccine impact on rates of SARS-CoV-2 cases and post vaccination
- 550 strain sequences among healthcare workers at an urban academic medical center: a prospective
- cohort study. medRxiv. 2021 Jan 1.
- 552 38. Tenforde MW. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among
- 553 Hospitalized Adults Aged≥ 65 Years—United States, January–March 2021. MMWR. Morbidity and
- mortality weekly report. 2021;70.
- 555 39. Swift MD, Breeher LE, Tande AJ, Tommaso CP, Hainy CM, Chu H, Murad MH, Berbari EF, Virk A.
- Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare
- personnel. Clinical Infectious Diseases. 2021 Apr 26.
- 558 40. Mason TF, Whitston M, Hodgson J, Watkinson RE, Lau YS, Abdulrazeg O, Sutton M. Effects of
- 559 BNT162b2 mRNA vaccine on COVID-19 infection and hospitalization among older people: matched
- case control study for England. medRxiv. 2021 Jan 1.
- 561 41. Gras-Valentí P, Chico-Sánchez P, Algado-Sellés N, Jiménez-Sepúlveda NJ, Gómez-Sotero IL, Fuster-
- Pérez M, Cartagena-Llopis L, Sánchez-Valero M, Cerezo-Milán P, Martínez-Tornero I, Tremiño-
- Sánchez L. Effectiveness of the first dose of BNT162b2 vaccine to preventing COVID-19 in
- healthcare personnel. Revista Espanola de Salud Publica. 2021 Apr 29;95.
- 565 42. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, Wellington E, Stowe J, Gillson N, Atti A,
- Islam J. COVID-19 vaccine coverage in health-care workers in England and effectiveness of

- BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. The Lancet. 2021 May 8;397(10286):1725-35.
- 569 43. Britton A, Slifka KM, Edens C, Nanduri SA, Bart SM, Shang N, Harizaj A, Armstrong J, Xu K, Ehrlich
- 570 HY, Soda E. Effectiveness of the Pfizer-BioNTech COVID-19 vaccine among residents of two skilled
- 571 nursing facilities experiencing COVID-19 outbreaks—Connecticut, December 2020–February 2021.
- 572 Morbidity and Mortality Weekly Report. 2021 Mar 19;70(11):396.
- 573 44. Monge S, Olmedo C, Alejos B, Lapena M, Sierra MJ, Limia A. Direct and indirect effectiveness of
- 574 mRNA vaccination against SARS-CoV-2 infection in long-term care facilities in Spain. medRxiv. 2021
- 575 Jan 1.
- 576 45. Hyams C, Marlow R, Maseko Z, King J, Ward L, Fox K, Heath R, Turner A, Friedrich Z, Morrison L,
- 577 Ruffino G. Assessing the effectiveness of BNT162b2 and ChAdOx1nCoV-19 COVID-19 vaccination in
- 578 prevention of hospitalizations in elderly and frail adults: a single centre test negative case-control
- 579 study.
- 580 46. Angel Y, Spitzer A, Henig O, Saiag E, Sprecher E, Padova H, Ben-Ami R. Association between
- vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections
- among health care workers. JAMA. 2021 May 6.
- 583 47. Corchado-Garcia J, Hughes T, Cristea-Platon T, Lenehan P, Pawlowski C, Bade S, O'Horo JC, Gores
- 584 GJ, Williams AW, Badley AD, Halamka J. Real-world effectiveness of Ad26. COV2. S adenoviral
- vector vaccine for COVID-19.
- 586 48. COVID EA. Vaccine: EMA Finds Possible Link to very Rare Cases of Unusual Blood Clots with Low
- 587 Blood Platelets.
- 588 49. Ma LL, Wang YY, Yang ZH, Huang D, Weng H, Zeng XT. Methodological quality (risk of bias)
- assessment tools for primary and secondary medical studies: what are they and which is better?.
- 590 Military Medical Research. 2020 Dec;7(1):1-1.
- 591 50. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K,
- 592 Southern J. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and
- 593 COVID-19 cases, hospitalizations, and deaths following a nationwide vaccination campaign in Israel:
- an observational study using national surveillance data. The Lancet. 2021 May 15;397(10287):1819-
- 595 29.
- 596 51. Lumley SF, Rodger G, Constantinides B, Sanderson N, Chau KK, Street TL, O'Donnell D, Howarth A,
- 597 Hatch SB, Marsden BD, Cox S. An observational cohort study on the incidence of SARS-CoV-2
- infection and B. 1.1. 7 variant infection in healthcare workers by antibody and vaccination status.
- 599 medRxiv. 2021 Jan 1.
- 600 52. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J,
- 601 Hu C. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID


602 Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases. 603 2021 Apr 27. 604 53. Drury RE, O'Connor D. Symptom study app provides real-world data on COVID-19 vaccines. Lancet 605 Infect Dis. 2021 Jul;21(7):890-891. doi: 10.1016/S1473-3099(21)00264-4. Epub 2021 Apr 27. PMID: 606 33930321; PMCID: PMC8078875. 607 54. Thompson MG, Burgess JL, Naleway AL, Tyner HL, Yoon SK, Meece J, Olsho LEW, Caban-Martinez 608 AJ, Fowlkes A, Lutrick K, Kuntz JL, Dunnigan K, Odean MJ, Hegmann KT, Stefanski E, Edwards LJ, 609 Schaefer-Solle N, Grant L, Ellingson K, Groom HC, Zunie T, Thiese MS, Ivacic L, Wesley MG, 610 Lamberte JM, Sun X, Smith ME, Phillips AL, Groover KD, Yoo YM, Gerald J, Brown RT, Herring MK, 611 Joseph G, Beitel S, Morrill TC, Mak J, Rivers P, Harris KM, Hunt DR, Arvay ML, Kutty P, Fry AM, 612 Gaglani M. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 613 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and 614 Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021. MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495-500. doi: 10.15585/mmwr.mm7013e3. PMID: 615 616 33793460; PMCID: PMC8022879. 617 55. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, Bedston S, Beggs J, Bradley D, Chuter A, 618 de Lusignan S, Docherty AB, Ford D, Hobbs FR, Joy M, Katikireddi SV, Marple J, McCowan C, McGagh 619 D, McMenamin J, Moore E, Murray JL, Pan J, Ritchie L, Shah SA, Stock S, Torabi F, Tsang RS, Wood R, 620 Woolhouse M, Robertson C, Sheikh A. Interim findings from first-dose mass COVID-19 vaccination 621 roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 622 2021 May 1;397(10285):1646-1657. doi: 10.1016/S0140-6736(21)00677-2. Epub 2021 Apr 23. 623 PMID: 33901420; PMCID: PMC8064669. 624 625 626 Web appendix: Supplementary material

627

Figure 1) Experimental group follow-up: the dashed line represents the *induction time* for the first and the second vaccine doses respectively. The solid line underpins the follow-up period.



- 1
- first dose uptake (a). Forest plot, fully vaccinated. Any positive PCR RR [95%-CI] ≥7 days from full 2
- vaccination (b). Forest plot, any positive PCR RR [95%-CI], ≥14 days from vaccination with at least 3
- one dose. IV method (c). 4



b) Fully vaccinated, any positive PCR

	Expe	rimental		Control	Weight	Weight	Risk Ratio	Risk Ratio
Study	Events	Total	Events	Total	(fixed)	(random)	IV, Fixed + Random, 95% CI	IV, Fixed + Random, 95% CI
Benenson	9	5239	213	6252	1.2%	5.9%	0.05 [0.03; 0.10]	
Britton	7	304	39	87	0.9%	5.8%	0.05 [0.02; 0.11]	
Dagan	55	392560	6100	592486	7.5%	6.1%	0.01 [0.01; 0.02]	• ii
Daniel	4	8121	234	8969	0.5%	5.6%	0.02 [0.01; 0.05]	→
Hall	8	1605	902	1405	1.1%	5.9%	0.01 [0.00; 0.02]	-
Lopez Bernal B80	69	1175	8988	24706	10.1%	6.1%	0.16 [0.13; 0.20]	=
Pawloski	159	31069	437	31069	16.2%	6.2%	0.36 [0.30; 0.44]	i i 🙃
Bouton	17	5913	329	3481	2.2%	6.0%	0.03 [0.02; 0.05]	
Tenforde	1	19	146	287	0.1%	4.5%	0.10 [0.02; 0.70]	-
Pritchard	72	373402	11697	373402	9.9%	6.1%	0.01 [0.00; 0.01]	•
Sansone	40	6904	48056	1247583	5.5%	6.1%	0.15 [0.11; 0.20]	i 🗕
Swift	30	44011	997	23931	4.0%	6.1%	0.02 [0.01, 0.02]	•
Angel	19	5372	17	696	1.3%	5.9%	0.14 [0.08; 0.28]	÷
Abu Raddad A	50	515	16354	32293	7.6%	6.1%	0.19 [0.15; 0.25]	. i .
Abu Raddad B	179	877	19396	38273	30.9%	6.2%	0.40 [0.35; 0.46]	1 -
Corchado	3	1779	128	17744	0.4%	5.5%	0.23 [0.07; 0.73]	 -
Fabiani	4	5182	26	1064	0.5%	5.6%	0.03 [0.01; 0.09]	
Total (fixed effect, 95% CI)		884047		2403728	100.0%		0.12 [0.11; 0.13]	
Total (random effects, 95% CI)		004047		2403720	100.076	100.0%	0.06 [0.03; 0.13]	≟ ' ∣
Heterogeneity: Tau ² = 2.6335; Chi ²		df = 16	(P = 0): I ²	= 99%	-	100.076	0.00 [0.03, 0.13]	
,,		,	//-					0.01 0.1 1 10 100

c) At least one dose, any positive PCR

	Expe	erimental		Control	Weight	Weight	Risk Ratio			Ris	sk Ra	tio	
Study	Events	Total	Events	Total	(fixed)		IV, Fixed + Random, 95% C	IN	, Fixe	d + F	Rand	om, 959	6 C
Amit	81	7214	89	1895	0.3%	5.5%	0.24 [0.18; 0.32]			+	300		
Benenson	54	5297	213	6252	0.3%	5.5%	0.30 [0.22; 0.40]			-			
Britton	32	376	39	87	0.2%	5.3%	0.19 [0.13; 0.28]			+-!			
Dagan	927	592356	6100	592486	5.5%	5.7%	0.15 [0.14; 0.16]			0	8		
fall	74	13716	902	1405	0.5%	5.6%	0.01 [0.01; 0.01]	+					
opez Bernal C70	803	12122	15287	51955	5.7%	5.7%	0.23 [0.21; 0.24]						
Lopez Bernal C80	794	4378	8988	24706	6.2%	5.7%	0.50 [0.47; 0.53]				u		
umley A	44	8285	635	10513	0.3%	5.5%	0.09 [0.06; 0.12]		-				
umley B	12	2738	635	10513	0.1%	5.0%	0.07 [0.04; 0.13]		-	- 1	8		
Moustsen Helms H	275	91865	5663	239174	1.8%	5.7%	0.13 [0.11; 0.14]		178	•			
Moustsen Helms R	268	37172	488	1868	1.3%	5.7%	0.03 [0.02; 0.03]				8		
Pawloski	263	31069	661	31069	1.3%	5.7%	0.40 [0.35: 0.46]						
ande	42	3006	1436	45327	0.3%	5.5%	0.44 [0.33; 0.60]			1	-		
Bouton	29	7109	329	3481	0.2%	5.4%	0.04 [0.03: 0.06]				ê		
Monge	11304	296093	19656	296093	51.5%	5.7%	0.58 [0.56; 0.59]						
Mason	764	130736	1413	130736	3.4%	5.7%	0.54 [0.50; 0.59]				•		
Jenni A	2465	64828	50340	414016	16.8%	5.7%	0.31 [0.30; 0.33]				ů l		
Menni B	641	35688	50340	415016	4.4%	5.7%	0.15 [0.14; 0.16]						
Total (fixed effect, 95% CI)		1344048		2276592	100.0%		0.38 [0.38; 0.39]			П			
Total (random effects, 95% CI)						100.0%	0.16 [0.11; 0.23]		- 8	٠			
leterogeneity: Tau ² = 0.5862; Chi ² :	= 5954.33	df = 17 (F	= 0): I2 =	100%				1					_
, , , , , , , , , , , , , , , , , , , ,			- n					0.0	0.	1	1	10	1

medRxiv preprint doi: https://doi.org/10.1101/2021.08.25.21262529; this version posted August 28, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission.

Figure 3) Forest plot, symptomatic positive SARS-CoV-2 PCR RR [95%-CI] ≥ 14 days from first dose uptake (a). Forest plot, fully vaccinated. Symptomatic positive PCR RR [95%-CI] ≥7 days from full vaccination (b). IV method.

a) Partially vaccinated, symptomatic positive PCR

	Expe	rimental		Control	Weight	Weight	Risk Ratio	Risk Ratio
Study	Events	Total	Events	Total	(fixed)	(random)	IV, Fixed + Random, 95% CI	IV, Fixed + Random, 95% CI
Amit	11	7214	60	1895	0.5%	11.0%	0.05 [0.03; 0.09]	
Dagan	2373	263179	3433	262662	83.4%	11.4%	0.69 [0.65; 0.73]	•
Hyams A	18	108	117	296	1.1%	11.2%	0.42 [0.27; 0.66]	 -
Hyams B	9	62	27	64	0.5%	11.0%	0.34 [0.18; 0.67]	
Pritchard	157	361705	5993	373402	9.0%	11.4%	0.03 [0.02; 0.03]	•
Swift	66	3112	876	22934	3.7%	11.3%	0.56 [0.43; 0.71]	+
Angel	31	5761	37	741	1.0%	11.2%	0.11 [0.07; 0.17]	→ !
Jones	4	1989	26	3252	0.2%	10.4%	0.25 [0.09; 0.72]	
Fabiani	9	147	116	1090	0.5%	11.0%	0.58 [0.30; 1.11]	+
Total (fixed effect, 95% CI)		643277		666336	100.0%	_	0.49 [0.47; 0.51]	
Total (random effects, 95% Cl) Heterogeneity: Tau ² = 3.0607; Chi ²). df = 8 (F	P = 0): I ² =	= 99%	-	100.0%	0.22 [0.07; 0.69]	
		, (-	-71					0.1 0.5.1.2 10

b) Fully vaccinated, symptomatic positive PCR

	Experimen	tal	Control	Weight	Weight	Risk Ratio	Risk Ratio
Study	Events To	tal Events	Total	(fixed)	(random)	IV, Fixed + Random, 95% CI	IV, Fixed + Random, 95% CI
Dagan	16 1092	61 174	108242	3.0%	12.7%	0.09 [0.05; 0.15]	 - -
Pritchard	12 3617	05 5993	373402	2.5%	12.6%	0.00 [0.00; 0.00]	-
Swift	22 439	81 876	22934	4.4%	12.8%	0.01 [0.01; 0.02]	+
Angel	8 53	72 38	696	1.4%	12.1%	0.03 [0.01; 0.06]	→
Abu Raddad A	51 513	24 962	162434	10.0%	13.0%	0.17 [0.13; 0.22]	•
Abu Raddad B	201 513	24 1768	162434	37.4%	13.1%	0.36 [0.31; 0.42]	.
Abu Raddad C	222 513	24 1756	162434	40.8%	13.1%	0.40 [0.35; 0.46]	•
Fabiani	4 51	86 6	1090	0.5%	10.6%	0.14 [0.04; 0.50]	+++
Total (fixed effect, 95% CI)	6794	77	993666	100.0%		0.24 [0.22; 0.27]	
Total (random effects, 95% CI)				-	100.0%	0.06 [0.02; 0.16]	-
Heterogeneity: Tau ² = 1.7560; Chi ²	= 586.13, df = 7	(P < 0.01);	² = 99%				1 1 1 1 1
- '							0.01 0.1 1 10 100

Fig. 4) L'Abbè plots. Partially vaccinated, any positive SARS-CoV-2 PCR RR ≥14 days from first SARS-CoV-2 dose administration (a). Fully vaccinated, any positive PCR RR, ≥7 days from full vaccination (b). At least one dose, any positive PCR RR ≥14 days from vaccination with first dose (c). Partially vaccinated, symptomatic positive PCR RR ≥14 days from first dose administration (d). Fully vaccinated, symptomatic positive SARS-CoV-2 PCR RR ≥7 days from full vaccination (e). The sizes of the plotted circles are proportional to the precision of the studies. The dashed lines marked the overall estimate of the log risk for RE (light) and FE (bold). The further the circle from the line of no effect, the greater the difference of event rates between intervention and control arms.

